Home / Medications for Opioid Use Disorder
TREATMENT OPTIONS
A neutral, evidence-based guide to the three FDA-approved medications for opioid use disorder: what they are, how they work, and what questions to ask a clinician.
EVIDENCE LEVEL: ESTABLISHED / CLINICAL GUIDANCE
· 8 min read
On this page
Why Medication May Be Recommended
Comparing the Three Medications
Is MOUD Replacing One Addiction?
Opioid use disorder (OUD) is a treatable medical condition. Three medications are FDA-approved specifically for its treatment: buprenorphine, methadone, and naltrexone. Collectively they are referred to as Medications for Opioid Use Disorder (MOUD), sometimes also called medication-assisted treatment (MAT).
SAMHSA identifies these three as the evidence-based cornerstone of OUD treatment. Used in combination with counseling and support services, they significantly reduce cravings, prevent relapse, lower overdose mortality, and improve long-term outcomes. [1]
This page provides a clear overview of each medication, a neutral comparison, and answers to common questions, including the one asked most often: "Is this just replacing one addiction with another?"
QUICK ANSWER
Buprenorphine, methadone, and naltrexone are the three FDA-approved medications for OUD. All three reduce the risk of relapse and overdose death. They work through different mechanisms and suit different clinical situations. None is universally "best": the right choice depends on individual circumstances and should be made with a clinician.
MOUD refers to the use of FDA-approved medications, in combination with counseling and psychosocial support, to treat opioid use disorder. The goal is not simply to manage withdrawal symptoms, but to address the longer-term neurobiological and behavioral dimensions of OUD.
MOUD is grounded in decades of research. It is the standard of care recommended by SAMHSA, the American Society of Addiction Medicine (ASAM), and major international health bodies. [1, 2]
After acute withdrawal, many people return to opioid use, not because of weak willpower, but because:
• Cravings driven by changes in brain reward circuits persist long after physical withdrawal resolves
• Stress, environmental cues, and emotional triggers can produce powerful urges to use
• Tolerance drops during abstinence, meaning a return to use at a previous dose can be fatal
• The underlying neurobiological adaptations of OUD do not fully reverse in a short timeframe
MOUD medications work with the brain's opioid receptor system, rather than demanding that the system immediately normalize, to reduce cravings and block the reinforcing effects of illicit opioids. Evidence consistently shows that MOUD reduces overdose deaths, reduces illicit opioid use, and improves quality of life. [1]
Partial opioid agonist
Buprenorphine is a partial opioid agonist: it activates mu-opioid receptors, but less strongly than full agonists like heroin or oxycodone. This partial activation is enough to reduce cravings and withdrawal symptoms without producing significant euphoria at therapeutic doses. It also has a "ceiling effect" on respiratory depression, making it much safer in overdose than full agonists.
Common formulations
Sublingual film (Suboxone, buprenorphine/naloxone), sublingual tablets (Subutex), monthly injectable (Sublocade), six-month implant (Probuphine).
Naloxone combination
Most formulations combine buprenorphine with naloxone (an opioid antagonist) to deter injection misuse. When taken as directed sublingually, the naloxone is minimally absorbed and has no meaningful effect.
Access
Can be prescribed by certified physicians, nurse practitioners, and physician assistants, including in office-based and telehealth settings. Since 2023, the X-waiver requirement has been eliminated in the U.S., broadening prescriber access significantly.
Induction
Buprenorphine must be initiated when the person is in mild-to-moderate withdrawal (not in a fully saturated state) to avoid precipitated withdrawal.
Duration
Can be used short-term for withdrawal management or long-term for OUD treatment. Evidence generally supports longer duration of treatment for better outcomes.
SAMHSA describes buprenorphine as reducing illicit opioid use and increasing treatment retention. [1]
See: Buprenorphine Explained →Full opioid agonist
Methadone is a full opioid agonist with a long half-life (24–36+ hours). At stable therapeutic doses, it eliminates withdrawal symptoms and reduces cravings throughout the day without producing euphoria, because blood levels remain stable rather than spiking.
Treatment setting
For OUD treatment, methadone must be dispensed through federally licensed Opioid Treatment Programs (OTPs), typically as a daily oral dose administered at a clinic.
Stability
Stable patients may earn take-home doses over time, reducing the burden of daily clinic visits.
Safety considerations
Methadone has a narrow therapeutic window and can affect heart rhythm (QT prolongation) at higher doses. Dose adjustments require clinical monitoring.
Long-term use
Research supports long-term methadone maintenance. Stopping methadone requires a supervised, gradual taper: abrupt discontinuation is not recommended.
Who it may suit
People who have not responded to buprenorphine, those requiring a more structured treatment setting, or those with more severe OUD.
Opioid antagonist
Naltrexone is an opioid antagonist: it blocks opioid receptors entirely, preventing any opioid from producing its effects. Unlike buprenorphine and methadone, it has no opioid agonist activity and cannot be misused to get high.
Formulations
Oral tablet (ReVia, daily) or extended-release injectable (Vivitrol, monthly).
Opioid-free requirement
Because naltrexone is an antagonist, it will precipitate severe, immediate withdrawal if taken while opioids are still in the system. A person must be fully opioid-free for 7–10 days (longer for methadone) before initiation.
No physical dependence
Naltrexone does not produce physical dependence. Stopping it does not cause withdrawal.
Mechanism
By blocking opioid receptors, naltrexone removes the reinforcing effect of opioids: if a person uses while on naltrexone, they will feel little or no effect.
Adherence
Adherence with oral naltrexone can be a challenge. The monthly injectable formulation (Vivitrol) addresses this by removing the need for daily dosing.
Who it may suit
People who are highly motivated, have completed opioid detox, prefer a non-opioid treatment, or have professional/legal reasons to avoid agonist medications.
Feature
Buprenorphine
Methadone
Naltrexone
Medication type
Partial opioid agonist
Full opioid agonist
Opioid antagonist
Helps with withdrawal
Yes
Yes
No (requires prior detox)
Reduces cravings
Yes
Yes
Yes (by blocking reward)
Physical dependence produced
Yes
Yes
No
Long-term use supported by evidence
Yes
Yes
Yes (adherence varies)
Access / setting
Office-based, telehealth, ED
Licensed OTP clinic (daily)
Office-based, monthly injectable
Opioid-free period required
Must be in mild withdrawal
No
7–10+ days fully opioid-free
Overdose safety
Higher (ceiling effect)
Lower (requires monitoring)
Highest (no agonist activity)
This is the most common question, and the most important one to address honestly.
The short answer: No. SAMHSA explicitly describes MOUD medications as evidence-based treatments, not as substituting one drug for another. [1]
Here is why the comparison does not hold up:
• OUD involves compulsive, harmful use despite negative consequences. A person on a stable therapeutic dose of buprenorphine or methadone is not experiencing compulsive, harmful use: they are taking a medication as prescribed that allows them to function normally.
• The neurobiological goals are different. MOUD medications stabilize the opioid receptor system at a consistent level, rather than producing the spikes and crashes of active opioid use that drive the cycle of compulsive behavior.
• Functional outcomes improve. Research shows people on MOUD have better employment, family, and health outcomes compared to those who attempt abstinence-only approaches.
• Mortality decreases significantly. MOUD reduces overdose deaths. The "replacement addiction" framing, when used to justify withholding effective treatment, contributes to preventable deaths.
The more accurate analogy is insulin for diabetes or blood pressure medication for hypertension: a chronic condition managed with medication that allows the person to live a healthy, functional life.
This is a decision that should be made with careful clinical planning, not abruptly.
• Stopping buprenorphine or methadone abruptly will produce withdrawal and significantly increase relapse risk.
• A supervised taper is the standard approach, individualized to the person's situation.
• There is no standard "right" duration of MOUD. Some people choose to continue long-term; others eventually taper successfully. Both are valid outcomes.
• The decision to discontinue MOUD should never be driven by external pressure: stigma, cost, or a provider's preference: but by the person's own goals, medical situation, and readiness, assessed collaboratively with a clinician.
Do not stop MOUD abruptly without clinical guidance. Abrupt discontinuation significantly increases the risk of relapse and, because tolerance drops rapidly, the risk of a fatal overdose on return to use.
Detox (withdrawal management) and MOUD are not equivalent. Detox manages the physical symptoms of withdrawal: it does not treat opioid use disorder. Evidence consistently shows that detox alone, without ongoing MOUD or other treatment, is associated with high rates of return to use. [2]
Detox can be an important first step, but for most people with OUD, it should be followed by ongoing treatment, of which MOUD is the most evidence-supported form. See: MOUD vs. Detox: What's the Difference?
If you are considering MOUD, these questions can help you make an informed decision:
1. Which medication would you recommend for my situation, and why?
2. What does the induction process look like: what do I need to do first?
3. How will we monitor my progress and adjust the dose?
4. What are the most common side effects I should expect?
5. How long do most of your patients stay on this medication?
6. What happens if I miss a dose or want to stop?
7. What counseling or support services do you recommend alongside medication?
8. What does discontinuation look like when/if I choose to stop?
For a comprehensive preparation guide: How to Prepare for a Conversation With a Treatment Provider
SAMHSA Helpline
1-800-662-4357 (free, confidential, 24/7)
FindTreatment.gov
findtreatment.gov: treatment program locator
Prescriber Locator
samhsa.gov: SAMHSA buprenorphine practitioner locator
• Buprenorphine, methadone, and naltrexone are FDA-approved, evidence-based treatments for OUD.
• MOUD reduces overdose deaths, illicit opioid use, and relapse, with strong evidence across decades of research.
• Each medication works differently and suits different clinical situations. No single option is universally "best."
• MOUD is not "replacing one addiction with another." It is treating a medical condition with proven medicine.
• Stopping MOUD should be planned with a clinician: abrupt discontinuation significantly increases risk.
• Detox alone is not equivalent to OUD treatment.
1. SAMHSA. Medications for Opioid Use Disorder: Treatment Improvement Protocol (TIP) 63. 2021. SAMHSA.gov
2. Volkow ND, Frieden TR, Hyde PS, Cha SS. Medication-assisted therapies, tackling the opioid-overdose epidemic. N Engl J Med. 2014;370(22):2063-2066. PubMed
3. Mattick RP, et al. Methadone maintenance versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev. 2009. PubMed
4. CDC. Evidence-Based Overdose Prevention Strategies. CDC.gov
This page provides general educational information. MOUD decisions should be made in collaboration with a licensed healthcare provider. Last reviewed: August 2026. For educational purposes only.
Opiate Freedom Foundation is affiliated with PowerMade.com, which sells supplements.